UNIVERSITÉ DE GENÈVE

Archive ouverte UNIGE
https://archive-ouverte.unige.ch

Article scientifique | Article | 2023

Appendix | Open Access

This file is a(n) Appendix of:

# Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

Mellinghoff, Ingo K; van den Bent, Martin J; Blumenthal, Deborah T; Touat, Mehdi; Peters, Katherine B; Clarke, Jennifer; Mendez, Joe; Yust-Katz, Shlomit; Welsh, Liam; Mason, Warren P; Ducray, François; Umemura, Yoshie; Nabors, Burt; Holdhoff,&nbspMatthias [**and 16 more**]

Collaborators: Migliorini, Denis

This publication URL: https://archive-ouverte.unige.ch/unige:173928
Publication DOI: 10.1056/NEJMoa2304194

© This document is protected by copyright. Please refer to copyright holders for terms of use.

RESEARCH SUMMARY

# Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

Mellinghoff IK et al. DOI: 10.1056/NEJMoa2304194

## CLINICAL PROBLEM

Gliomas, the most common malignant primary brain tumor type in adults, are categorized by histologic and molecular features and by tumor grade. Almost all grade 2 gliomas have mutations in the genes encoding the metabolic enzymes isocitrate dehydrogenase 1 (IDH1) or 2 (IDH2).

## CLINICAL TRIAL

**Design:** This phase 3, double-blind, randomized, placebo-controlled trial tested the clinical effects of vorasidenib — an oral brain-penetrant inhibitor of mutant IDH1 and IDH2 enzymes — in patients with residual or recurrent grade 2 IDH-mutant glioma who had undergone surgery as their only previous treatment.

**Intervention:** 331 patients were assigned to receive oral vorasidenib (40 mg once daily) or matched placebo in 28-day cycles. The primary end point was imaging-based progression-free survival.

## RESULTS

**Efficacy:** Progression-free survival was significantly longer with vorasidenib than with placebo.

**Safety:** Although most adverse events with vorasidenib were mild, events of grade ≥3 were more frequent with vorasidenib than with placebo; the most common was an increase in alanine aminotransferase level. Serious adverse events that were determined by the investigators to be related to the trial drug or placebo occurred in 1.8% of vorasidenib recipients and in no placebo recipients.

## LIMITATIONS AND REMAINING QUESTIONS

- Patients with high-risk features were excluded from the trial.
- Additional end points, including health-related quality of life and neurocognition, were not reported.
- Results for the overall survival end points remain to be determined.

**Links: Full Article | NEJM Quick Take | Editorial | Science behind the Study**










## CONCLUSIONS

**Among patients with grade 2 IDH-mutant glioma, progression-free survival was significantly longer with vorasidenib than with placebo.**

Copyright © 2023 Massachusetts Medical Society.